Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
'Kim Possible'
'The Kissing Booth'
Haiti
X-ray girl
Illinois shooting
'American Girl'
Sarah Sanders
Orangutan
Japan's Ainu
Roger Stone
Climate change
Daytona 500
Health News
Jan. 18, 2019 / 4:51 PM

Common gut bacteria blocks effects of Parkinson's drugs, study says

By
Tauren Dyson
Gut bacteria metabolizes levodopa, a common Parkinson's medication, into dopamine, a neurotransmitter in the brain, which reduces the drug's effectiveness, researchers say. Photo by Juan Gaertner/Shutterstock

Jan. 18 (UPI) -- A common gut bacteria can block a common Parkinson's disease medicine from working on patients with the disease, a new study says.

Gut bacteria metabolizes levodopa, a common Parkinson's medication, into dopamine, a neurotransmitter in the brain. Since dopamine can't pass through the blood-brain barrier, it saps the levodopa of its effectiveness, according to a study published Friday in the journal Nature Communications.

"It is well established that gut bacteria can affect the brain," Sahar El Aidy, an assistant professor in microbiology at University of Groningen and study lead investigator, said in a news release. "There is a continuous chemical dialogue between gut bacteria and the brain, the so-called gut-brain axis."

The less effect a normal dosage of levodopa has on a Parkinson's patient, the more of the drug a doctor will administer. This can lead to dyskinesia, a condition that causes involuntary movements and severe pain.

So the researchers needed to zero in on the cause of the conversion to dopamine. Since decarboxylase enzymes convert levodopa to dopamine, doctors gave test rats with Parkinson's a decarboxylase inhibitor to block that conversion.

"We then determined that the source of this decarboxylase was Enterococcus bacteria," Sebastiaan van Kessel said.

To prevent decarboxylase from turning levodopa into dopamine, the researchers injected the test rats with a decarboxylase inhibitor called Carbidopa.

"It turned out that the inhibitor Carbidopa is over 10,000 times more potent in inhibiting the human decarboxylase," El Aidy said.

Read More

New test locates protein linked to Alzheimer's, CTE Coffee could fight Parkinson's disease, study says
  • Topics
  • Parkinson's
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Post-menopausal women who drink diet soda have increased stroke risk
Irregular heartbeat triggers can easily be altered
Study: Chemical in Roundup may increase cancer risk by 40 percent
Hip and knee replacements show high durability, study shows
People with sleep apnea three times as likely to have heart failure

Photo Gallery

 
Lunar New Year celebrations in Beijing

Latest News

Latin America's female leaders seek to make up for setback in roles
A Boogie Wit da Hoodie's 'Hoodie SZN' tops U.S. album chart
Nigeria postpones presidential election at last minute
Academy reverses decision: All Oscars to be presented live on air
Aurora, Ill., gunman faced being fired before deadly shooting
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy